• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Switzerland·Healthcare·BIIO
Share

Bionovate Technologies Corp Stocks

$ 0Last Updated 26.08.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 775

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bionovate Technologies Corp. is a medical device enterprise dedicated to pioneering automated solutions for the treatment of age spots. Its core objective is to engineer a sophisticated, computer-driven system designed to precisely target and treat these blemishes on any area of the body. The firm plans to distribute these advanced systems globally, marketing them to healthcare providers and wellness centers. Founded in Cham, Switzerland, in 2010, the organization previously traded under the name MJP International Ltd. before adopting Bionovate Technologies Corp. in December 2017. Since October 7, 2020, the company has operated as an affiliated entity of Human Data AG.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.08.2026 23:34

"Worsha was seen as a hawk": The market sharply raised expectations for a rate hike in September

28.08.2026 21:40

"The Schrodinger's Cat Situation": Analysts Take Stock of Six Months of the U.S.-Iran War

28.08.2026 20:58

BioNTech and Roche have halted a cancer vaccine trial. What does this mean for the industry?

28.08.2026 19:14

The Fed "has a lot of work ahead" if inflation doesn't come down quickly — Warsh

28.08.2026 19:05

"The Main Focus for the Markets": What to Expect from the Fed Chair's Speech in Jackson Hole

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026